Nuveen LLC Purchases Shares of 857,570 Cardiff Oncology, Inc. $CRDF

Key Points

• Nuveen LLC has acquired a new position in Cardiff Oncology, Inc. ($CRDF) during the 1st quarter, purchasing 857,570 shares valued at approximately $2.69 million.
• Cardiff Oncology stock is currently down 4.1%, with a market capitalization of $138.37 million and recent earnings missing analysts' expectations.
• Several analysts maintain a consensus rating of "Moderate Buy" for CRDF, with an average target price of $10.10 amid mixed performance outlooks.

Nuveen LLC purchased a new position in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 857,570 shares of the company's stock, valued at approximately $2,693,000. Nuveen LLC owned 1.29% of Cardiff Oncology at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of CRDF. BNP Paribas Financial Markets purchased a new stake in shares of Cardiff Oncology during the 4th quarter worth approximately $25,000. Ledgewood Wealth Advisors LLC purchased a new stake in Cardiff Oncology during the 1st quarter valued at $35,000. Castleview Partners LLC bought a new position in Cardiff Oncology in the 1st quarter valued at $45,000. ProShare Advisors LLC bought a new position in Cardiff Oncology in the 4th quarter valued at $50,000. Finally, Brighton Jones LLC bought a new position in Cardiff Oncology in the 1st quarter valued at $52,000. 16.29% of the stock is owned by hedge funds and other institutional investors.

Cardiff Oncology Price Performance

Cardiff Oncology stock traded up $0.02 during midday trading on Monday, reaching $2.10. The company's stock had a trading volume of 862,176 shares, compared to its average volume of 1,268,325. The stock's 50-day simple moving average is $3.12 and its 200-day simple moving average is $3.27. Cardiff Oncology, Inc. has a 52-week low of $2.06 and a 52-week high of $5.64. The stock has a market capitalization of $139.70 million, a P/E ratio of -2.41 and a beta of 1.29.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). Cardiff Oncology had a negative net margin of 9,344.14% and a negative return on equity of 77.94%. The business had revenue of $0.12 million during the quarter, compared to analysts' expectations of $0.11 million. As a group, equities research analysts expect that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Cardiff Oncology news, Director Gary W. Pace purchased 15,000 shares of the firm's stock in a transaction on Wednesday, July 30th. The stock was bought at an average cost of $2.45 per share, for a total transaction of $36,750.00. Following the completion of the purchase, the director owned 1,345,676 shares in the company, valued at $3,296,906.20. This represents a 1.13% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.70% of the company's stock.

Analyst Upgrades and Downgrades

CRDF has been the topic of a number of recent research reports. HC Wainwright dropped their price target on Cardiff Oncology from $18.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. LADENBURG THALM/SH SH started coverage on Cardiff Oncology in a research report on Tuesday, July 8th. They set a "buy" rating and a $19.00 price objective on the stock. Jefferies Financial Group started coverage on Cardiff Oncology in a research report on Tuesday, June 24th. They set a "hold" rating and a $3.50 price objective on the stock. Finally, William Blair reaffirmed an "outperform" rating on shares of Cardiff Oncology in a research report on Wednesday, June 18th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $10.10.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.